NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization709.23 mln
Float93.30 mln
Earnings Date08/06/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
18.80
Transformational upside
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.16
Very low leverage
ROE
-79.89
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aura Biosciences is a Boston-based clinical-stage company focused on developing targeted treatments for solid tumors. It uses a proprietary technology that attaches drugs or genetic material to virus-like particles, allowing them to seek out and attack cancer cells with greater precision. Its lead drug candidate, bel-sar, is being tested in advanced trials for eye melanoma and other eye cancers, as well as in earlier trials for bladder cancer.
